Skip to main content
Evidence Snapshot

Folate receptor alpha

CHEMBL2121 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:11Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2121
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Folate receptor alpha as ChEMBL target CHEMBL2121, mapped to UniProt P15328. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Folate receptor alpha
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2121
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P15328
Folate receptor alpha
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Folate receptor alpha matters

As of 2026-09-13

Folate receptor alpha is reviewed as Folate receptor alpha (UniProt P15328); Folate receptor alpha shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.; 3 linked drugs keep this evidence frame grounded.; the current evidence base includes 4 approved drugs, 105 compounds, and 34 assays, with lead potency reaching pChEMBL 9.8.

Disease context
neoplasm

Folate receptor alpha shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include FARLETUZUMAB, MIRVETUXIMAB SORAVTANSINE, VINTAFOLIDE.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include FARLETUZUMAB, MIRVETUXIMAB SORAVTANSINE, VINTAFOLIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 3 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 4 approved drugs, 105 compounds, and 34 assays for this target. The dominant activity type is IC50. CHEMBL4445651 is the current potency anchor at pChEMBL 9.8.

Use CHEMBL4445651 as the tractability anchor when discussing potency (pChEMBL 9.8).

Activity source · ChEMBL 36 via Core Engine
4 approved pChEMBL 9.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Folate receptor alpha matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P15328, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why neoplasm is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

105
Total Compounds
34
Total Assays
4
Approved Drugs
IC50: 93.0, KD: 21.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4445651
 9.8 IC50 —
No preferred name
CHEMBL85871
 9.8 Kd —
No preferred name
CHEMBL1834488
 9.5 IC50 —
No preferred name
CHEMBL3628344
 9.5 IC50 —
No preferred name
CHEMBL4790375
 9.5 IC50 —

Approved Drugs

Structure Compound First Approval
PRALATREXATE
CHEMBL1201746
 2009
PEMETREXED
CHEMBL225072
 2004
RALTITREXED
CHEMBL225071
 1996
METHOTREXATE
CHEMBL34259
 1953
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:11Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2121